Mereo BioPharma Files 8-K on Operations and Financials
Ticker: MREO · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1719714
| Field | Detail |
|---|---|
| Company | Mereo Biopharma Group PLC (MREO) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, regulatory-filing
TL;DR
Mereo BioPharma dropped an 8-K on financials and operations, standard stuff.
AI Summary
Mereo BioPharma Group plc filed an 8-K on March 27, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details in the provided text, but indicates a formal reporting event.
Why It Matters
This filing is a standard regulatory disclosure for Mereo BioPharma, providing investors with updates on the company's financial health and operational status.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for operational and financial reporting, not indicating any immediate material changes or risks.
Key Players & Entities
- Mereo BioPharma Group plc (company) — Registrant
- March 27, 2024 (date) — Date of earliest event reported
FAQ
What specific financial results are being reported in this 8-K?
The provided text of the 8-K filing does not contain specific financial figures or detailed results of operations.
What is the purpose of this 8-K filing for Mereo BioPharma Group plc?
This 8-K filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on the company's Results of Operations and Financial Condition, and Financial Statements and Exhibits.
When was this 8-K filing submitted?
The filing was submitted on March 27, 2024.
What is the company's jurisdiction of incorporation?
Mereo BioPharma Group plc is incorporated in England and Wales.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 574 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-03-27 16:08:00
Filing Documents
- d807451d8k.htm (8-K) — 28KB
- d807451dex991.htm (EX-99.1) — 80KB
- 0001193125-24-078800.txt ( ) — 290KB
- mreo-20240327.xsd (EX-101.SCH) — 4KB
- mreo-20240327_def.xml (EX-101.DEF) — 15KB
- mreo-20240327_lab.xml (EX-101.LAB) — 25KB
- mreo-20240327_pre.xml (EX-101.PRE) — 16KB
- d807451d8k_htm.xml (XML) — 7KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: Exhibit No. Description of Exhibit 99.1 Press Release, dated March 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. MEREO BIOPHARMA GROUP PLC Date: March 27, 2024 By: /s/ Christine Fox Name: Christine Fox Title: Chief Financial Officer